Company intelligenceABBV
AbbVie
NYSE · Pharmaceutical Preparations
Q2 FY2026Quarter ended Jun 30, 2026 (13-week quarter)Data as of Oct 19, 2026
This quarter's figures come from the company's SEC filing.
Blockhaven company read
Revenue grew 10.2% year over year, slowing from 12.4% in the prior quarter.
Operating margin expanded 613 basis points year over year to 37.9%. GAAP operating income rose 31.4% year over year to $6.43 billion.
Business trendMixedRevenue growth slowed, operating margin widened and GAAP operating income improved.
Latest reported quarter
13-week quarter
RevenueGAAP
- Latest
- $17 billion
- Year ago
- $15.4 billion
- Change
- +10.2% (Up year over year)
Operating incomeGAAP
- Latest
- $6.43 billion
- Year ago
- $4.89 billion
- Change
- +31.4% (Up year over year)
Net incomeGAAP
- Latest
- $3.61 billion
- Year ago
- $938 million
- Change
- +285.2% (Up year over year)
Diluted EPSGAAP
- Latest
- $2.03
- Year ago
- $0.52
- Change
- +290.4% (Up year over year)
Diluted sharesGAAP
- Latest
- 1.77 billion
- Year ago
- 1.77 billion
- Change
- 0.0% (Flat year over year)
Operating cash flowGAAP
- Latest
- $3.44 billion
- Year ago
- $5.15 billion
- Change
- −33.3% (Down year over year)
Derived from year-to-date filings
Capital expendituresGAAP
- Latest
- $322 million
- Year ago
- $269 million
- Change
- +19.7% (Up year over year)
Derived from year-to-date filings
Cash and equivalentsGAAP
- Latest
- $6.57 billion
- Year ago
- $6.47 billion
- Change
- +1.6% (Up year over year)
| Measure | Basis | Latest quarter | Year ago | Change |
|---|---|---|---|---|
| Revenue | GAAP | $17 billion | $15.4 billion | +10.2% (Up year over year) |
| Operating income | GAAP | $6.43 billion | $4.89 billion | +31.4% (Up year over year) |
| Net income | GAAP | $3.61 billion | $938 million | +285.2% (Up year over year) |
| Diluted EPS | GAAP | $2.03 | $0.52 | +290.4% (Up year over year) |
| Diluted shares | GAAP | 1.77 billion | 1.77 billion | 0.0% (Flat year over year) |
| Operating cash flowDerived from year-to-date filings | GAAP | $3.44 billion | $5.15 billion | −33.3% (Down year over year) |
| Capital expendituresDerived from year-to-date filings | GAAP | $322 million | $269 million | +19.7% (Up year over year) |
| Cash and equivalents | GAAP | $6.57 billion | $6.47 billion | +1.6% (Up year over year) |
This quarter's figures come from the company's SEC filing. GAAP unless labelled. Non-GAAP and company-defined measures are labelled.
Growth and margins
Revenue growth
+10.2%
Decelerating versus +12.4% in the prior quarter (year over year, GAAP).
Margins (GAAP)
- Operating margin 37.9%Expanded +613 bp vs 31.7% a year ago
- Net margin 21.3%Expanded +1518 bp vs 6.1% a year ago
Guidance
StatusNone found in the latest release
Recent events
- ManagementAn executive or director change (8-K Item 5.02)
Sources and dates
Filings and dates
- SEC filings (10-Q, 10-K financial data)
- Data as of Oct 19, 2026. Quarter ended Jun 30, 2026.
Data health
Figures cross-checked against SEC filings.
- SEC company recordAvailable
- SEC financial dataAvailable
- Earnings releaseUnavailable
Descriptive company facts from SEC filings and the issuer's own earnings release. GAAP figures are labelled as such. Not investment advice, a rating or a recommendation. Disclosures